A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A total of 474 adult patients with malignant glioma (astrocytoma) grade 3 or 4 were randomised into an MRC study (BR2) comparing 45 Gy (in 20 fractions over 4 weeks) with 60 Gy (in 30 fractions over 6 weeks) of radiotherapy given post-operatively. Using 2:1 randomisation, 318 patients were allocated the 60 Gy course and 156 the 45 Gy course. Adjuvant chemotherapy was not given. The results show that a 60 Gy course produces a modest lengthening of progression-free and overall survival. They suggest a statistically significant prolongation of median survival from 9 months in the 45 Gy group to 12 months in the 60 Gy group (hazard ratio = 0.75, chi 2 = 7.36, d.f. = 1, P = 0.007). Over 80% of patients reported no morbidity from the radiotherapy, and there was no evidence of increased short-term morbidity in the higher dose group. Late morbidity was not assessed. A prognostic index defined in a previous MRC study was validated in this new cohort. It identifies a group of patients (20% of the total) with a 2 year survival rate of 28% (95% confidence interval 19% to 38%). It was apparent that the survival advantage to the higher dose was maintained even in the poorest prognostic groups defined by this index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Walker, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,667
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Walker, M. D., Strike, T. A., & Sheline, G. E. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90553-4 · Cited by 854
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma
Wallner, K. E., Galicich, J. H., Krol, G., Arbit, E., & Malkin, M. G. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90941-3 · Cited by 782
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Chang, C. H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J. S., & Tsukada, Y. (1983) · Cancer · doi:10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2 · Cited by 598
Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Strike, T. A., et al. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.1.0001 · Cited by 458
Sb, G., Byar, D. P., Walker, Pistenmaa, D. A., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., Mealey, J., Gl, O., et al. (1983) · PubMed · Cited by 404
Cerebral radiation surgery using moving field irradiation at a linear accelerator facility
Hartmann, G. H., Schlegel, W., Sturm, V., Kober, B., Pastyr, O., & Lorenz, W. J. (1985) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(85)90068-9 · Cited by 291
Cited by
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 788
Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E. B., Werner-Wasik, M., Lustig, R., Schultz, C. J., Sause, W., Okunieff, P., Buckner, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.011 · Cited by 562
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Ruben, J. D., Dally, M., Bailey, M., Smith, R., McLean, C. A., & Fedele, P. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.12.002 · Cited by 492
Factors influencing survival in high-grade gliomas
Buckner, J. C. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.031 · Cited by 443
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
Laperriere, N., Zuraw, L., & Cairncross, G. (2002) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00078-6 · Cited by 424
Roa, W., Kepka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., Guedes de Castro, D., Dyttus-Cebulok, K., Drodge, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6606 · Cited by 340
By the Medical Research Council Brain Tumour Working Party (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.509 · Cited by 325
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Fisher, J. P., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030324 · Cited by 316
Lee, S. W., Fraass, B. A., Marsh, L. H., Herbort, K., Gebarski, S. S., Martel, M. K., Radany, E. H., Lichter, A. S., & Sandler, H. M. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00266-1 · Cited by 306
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Leder, K., Pitter, K., LaPlant, Q., Hambardzumyan, D., Ross, B. D., Chan, T. A., Holland, E. C., & Michor, F. (2014) · Cell · doi:10.1016/j.cell.2013.12.029 · Cited by 267
Fitzek, M. M., Thornton, A. F., Rabinov, J. D., Lev, M. H., Pardo, F. S., Munzenrider, J. E., Okunieff, P., Bussière, M., Braun, I., Hochberg, F. H., et al. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.91.2.0251 · Cited by 256
Verry, C., Dufort, S., Villa, J., Gavard, M., Iriart, C., Grand, S., Charles, J., Chovelon, B., Cracowski, J.-L., Quesada, J.-L., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.04.021 · Cited by 173
“The use of radiation sensitizers would therefore be of great interest specifically in increasing the effects of RT in tumors while sparing surrounding healthy tissues as RT dose-escalation can significantly improve local tumor control and survival [1,2].”
BackgroundChaichana, K. L., Pinheiro, L., & Brem, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.114 · Cited by 91
Temozolomide in the treatment of recurrent malignant glioma
Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D. (2004) · Cancer · doi:10.1002/cncr.11949 · Cited by 90
Metadata
- Authors
- on behalf of the Medical Research Council Brain Tumour Working Party, Bleehen, N., & Stenning, S.
- Venue
- British Journal of Cancer
- Published
- 1991-10
- Volume
- 64
- Issue
- 4
- Pages
- 769-774
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W80380620
- Cited by
- 414
- References
- 13
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.